This is a repository copy of Rescue therapy within the UK CF registry: an exploration of the predictors of IV antibiotic use amongst adults with cystic fibrosis.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/107374/

Version: Accepted Version

Proceedings Paper:

https://doi.org/10.1016/S1569-1993(16)30184-9

Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Background
IV antibiotics are needed for rescue when preventative therapy fails to achieve stability. Understanding the distribution of IV days among people with CF can provide insight into the care they need.

Aim
To determine baseline characteristics that are associated with higher IV use among adults with CF

Methods
The 2012 & 2013 data on age, sex, BMI, FEV1, pancreatic status, Pseudomonas status & CF related diabetes for those aged ≥16 years were obtained from the UK CF registry. IV days data for 2011-2013 were also obtained. Those on ivacaftor were excluded. Multiple regression was performed using current year IV days as the dependent variable and demographic variables & prior year IV days as the covariates for both 2012 & 2013. Based on these results, tree-based method (Zhang & Bracken, AJE 1996) was used to divide the study sample into clinically meaningful subgroups.

Results
For both years, prior year IV use was the strongest predictor for current year IV use, followed by FEV1. People with prior year IV use >14 days has a 4-6 fold increase in IV use for the subsequent year.

<table>
<thead>
<tr>
<th>Prior year IV ≤14 days and current FEV1 ≥70%</th>
<th>Prior year IV &gt;14 days and current FEV1 ≥70%</th>
<th>Prior year IV ≤14 days and current FEV1 &lt;70%</th>
<th>Prior year IV &gt;14 days and current FEV1 &lt;70%</th>
<th>One way ANOVA (comparing across the 4 groups) p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1617</td>
<td>485</td>
<td>1150</td>
<td>1480</td>
<td>2012: number of adults with CF</td>
</tr>
<tr>
<td>5.5 (11.2)</td>
<td>27.7 (28.1)</td>
<td>12.3 (19.9)</td>
<td>55.8 (50.2)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>0 (0-10)</td>
<td>22 (11-41)</td>
<td>0 (0-15)</td>
<td>43 (24-74)</td>
<td>2012: IV days, median (IQR)</td>
</tr>
<tr>
<td>1678</td>
<td>440</td>
<td>1148</td>
<td>1437</td>
<td>2013: number of adults with CF</td>
</tr>
<tr>
<td>4.7 (9.9)</td>
<td>26.6 (24.5)</td>
<td>12.8 (20.4)</td>
<td>53.8 (46.0)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>0 (0-0)</td>
<td>24 (7-41)</td>
<td>0 (0-14)</td>
<td>42 (24-71)</td>
<td>2013: IV days, median (IQR)</td>
</tr>
</tbody>
</table>

Conclusion
People with prior high levels of rescue will often continue to need high levels of rescue even if they have good lung function. The reasons for this require further investigations.

We thank the UK CF Registry for supplying the data for this analysis.

Preferred Presentation Type: Oral Presentation